Clinical trials: Seizures Disorders
Epilepsy
Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate
Zonisamide (Zonegran) and sodium valproate (Epilim) are both medicines approved to treat epilepsy. The purpose of this study is to find out the extent to which zonisamide may affect memory and concentration, compared to sodium…
- Trial name
- NCT00713622
- Testing
- Zonisamide, Sodium valproate
- Where
- 2 sites in Austria, Finland
- Volunteers
- 2 people
- Sponsor
- Eisai Limited
Hearing Loss
Comparison of Hearing Aid Fitting Outcomes Between Self-fit and Professional Fit for MDHearing Smart Hearing Aids
Hearing aids are commonly used to help people with hearing loss hear better in daily listening environments. MDHearing Smart hearing aids are designed to use the MDHearing app to adjust hearing aids to each individual's hearing…
- Trial name
- NCT05165121
- Testing
- MDHearing smart hearing aid
- Where
- United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- MDHearingAid
Epilepsy
Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures
To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic…
- Trial name
- NCT00334958
- Testing
- Rufinamide
- Where
- 77 sites in United States
- Volunteers
- 356 people
- Sponsor
- Eisai Inc.
Epilepsy, Seizures
Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
The objective of this study was to assess the bioequivalence of a potential generic 600 mg oxcarbazepine tablet formulation with Novartis Pharmaceutical's 600 mg oxcarbazepine tablet, Trileptal, folloiwng a single 600 mg dose…
- Trial name
- NCT00616863
- Testing
- Oxcarbazepine
- Where
- Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Generalized Tonic Clonic Seizures
A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.
The study is designed to evaluate the safety, tolerability and efficacy of two doses of pregabalin as add-on treatment in pediatric and adult subjects with Primary Generalized Tonic-Clonic (PGTC) seizures as compared to placebo.
- Trial name
- NCT01747915
- Testing
- Pregabalin Dose Level 1, Pregabalin Dose Level 2
- Where
- 127 sites in United States, Austria and 24 more
- Volunteers
- 219 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Partial Epilepsies
Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures
To evaluate the efficacy and safety of oral Lacosamide as first add on treatment in subjects with uncontrolled partial-onset seizures after prior treatment with a monotherapy Antiepileptic Drug (AED) regimen compared to subjects…
- Trial name
- NCT00955357
- Testing
- Lacosamide
- Where
- 109 sites in United States, Austria and 13 more
- Volunteers
- 461 people
- Sponsor
- UCB Pharma
Epilepsy, Partial-onset Seizures
Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures
EP0024 is a Phase 3, multicenter, open-label study to evaluate the safety and tolerability of intravenous (iv) lacosamide (LCM).
- Trial name
- NCT02192814
- Testing
- Lacosamide (200 mg/20 mL)
- Where
- 5 sites in Japan
- Volunteers
- 9 people
- Sponsor
- UCB Japan Co. Ltd.
Epilepsy, Partial Seizures
Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures
This study is aimed to collect additional data regarding the efficacy in reducing the frequency of partial seizures, as well as the safety and tolerability, of oxcarbazepine monotherapy in children.
- Trial name
- NCT00275912
- Testing
- Oxcarbazepine
- Where
- 5 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Novartis
Lennox-Gastaut Syndrome
A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)
To confirm that the combination therapy of rufinamide has superior efficacy compared to placebo in patients with Lennox-Gastaut syndrome.
- Trial name
- NCT01146951
- Testing
- Rufinamide (E2080)
- Where
- 23 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Eisai Limited
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Hearing Impairment
A Study Examining Acceptability of Auditory Implant Fitting Software Technologies
Auditory implant fitting software is used by hearing healthcare professionals to adjust and optimize hearing implant systems for people with hearing loss.
- Trial name
- SUNRISE-MU (NCT07763873)
- Testing
- Investigational Software
- Where
- 2 sites in United States, Australia
- Volunteers
- 200 people
- Sponsor
- Cochlear
Acute Repetitive Seizures
Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects
This study evaluates the pharmacokinetic and safety of NRL-1 in epilepsy subjects. Subjects will receive a single intranasal dose of NRL-1 of either 5 mg, 10 mg, 15 mg or 20 mg and will be based on the subject's body weight.
- Trial name
- NCT02724423
- Testing
- NRL-1
- Where
- 4 sites in United States
- Volunteers
- 57 people
- Sponsor
- Neurelis, Inc.
Tuberous Sclerosis Complex, Seizures
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P.
- Trial name
- NCT02544750
- Testing
- GWP42003-P
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Jazz Pharmaceuticals
Seizures
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Oxcarbazepine Suspension 600 mg under fed conditions
- Trial name
- NCT01703468
- Testing
- Oxcarbazepine
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Epilepsy, Epilepsies, Partial
An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy
The purpose of this study is to evaluate the safety and preliminary effectiveness of the novel compound RWJ-333369 in patients with partial onset seizures who are currently being treated with 1 or 2 concomitant antiepileptic…
- Trial name
- NCT00210652
- Testing
- RWJ 333369:
- Volunteers
- 47 people
- Sponsor
- SK Life Science, Inc.
Primary Generalized Tonic-Clonic or Partial Onset Seizures, Lennox Gastaut Syndrome
An Extended Access Program (EAP) for Perampanel
The main objective of this EAP is to ensure that participants participating in Study E2007-G000-332, Study E2007-G000-311, E2007-G000-238, E2007-G000-338 or EAP E2007-G000-401 continue to have access to perampanel until such time…
- Trial name
- NCT02307578
- Testing
- Perampanel
- Where
- 27 sites in Belgium, Chile and 8 more
- Sponsor
- Eisai Inc.
Epilepsy, Partial
A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.
To evaluate the safety and efficacy of levetiracetam used as adjunctive treatment in pediatric subjects age 1 month to less than 4 years with partial onset seizures.
- Trial name
- NCT00175890
- Testing
- Levetiracetam
- Where
- 86 sites in United States, Argentina and 13 more
- Volunteers
- 116 people
- Sponsor
- UCB Pharma
Post Stroke Epilepsy
Anti-epileptogenic Effects of Eslicarbazepine Acetate
This study aims to assess if eslicarbazepine acetate (ESL) treatment (started within 96 hours after stroke occurrence and continued for 30 days) changes the incidence of unprovoked seizures (USs) within the first 6 months after…
- Trial name
- NCT06597084
- Testing
- ESL 800 mg
- Where
- 22 sites in Austria, France and 7 more
- Volunteers
- 129 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy
Lamotrigine Extended-Release In Elderly Patients With Epilepsy
This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy. This study will be carried out using an extended-release formulation of lamotrigine (LTG-XR) that will…
- Trial name
- NCT00516139
- Testing
- Lamotrigine
- Where
- 63 sites in United States
- Volunteers
- 122 people
- Sponsor
- GlaxoSmithKline
Epilepsy
Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU
This study is designed to evaluate the efficacy, safety, and tolerability of USL261 compared with that of intranasal (IN) placebo for the treatment of intermittent bouts of increased seizure activity.
- Trial name
- NCT01999777
- Testing
- USL261
- Where
- 51 sites in United States, Australia and 6 more
- Volunteers
- 62 people
- Sponsor
- UCB Biopharma S.P.R.L.